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A mutation in caspase-9 decreases the expression of
BAFFR and ICOS in patients with immunodeficiency
and lymphoproliferation
N Clemente1, E Boggio1, CL Gigliotti1, E Orilieri1, G Cappellano1, E Toth1, PA Valletti1, C Santoro1, I Quinti2, C Pignata3, LD Notarangelo4,
C Dianzani5, I Dianzani1, U Ramenghi6, U Dianzani1 and A Chiocchetti1
Lymphocyte apoptosis is mainly induced by either death receptor-dependent activation of caspase-8 or mitochondria-dependent
activation of caspase-9. Mutations in caspase-8 lead to autoimmunity/lymphoproliferation and immunodeficiency. This work
describes a heterozygous H237P mutation in caspase-9 that can lead to similar disorders. H237P mutation was detected
in two patients: Pt1 with autoimmunity/lymphoproliferation, severe hypogammaglobulinemia and Pt2 with mild
hypogammaglobulinemia and Burkitt lymphoma. Their lymphocytes displayed defective caspase-9 activity and decreased
apoptotic and activation responses. Transfection experiments showed that mutant caspase-9 display defective enzyme and
proapoptotic activities and a dominant-negative effect on wild-type caspase-9. Ex vivo analysis of the patients’ lymphocytes and
in vitro transfection experiments showed that the expression of mutant caspase-9 correlated with a downregulation of BAFFR
(B-cell-activating factor belonging to the TNF family (BAFF) receptor) in B cells and ICOS (inducible T-cell costimulator) in T cells.
Both patients carried a second inherited heterozygous mutation missing in the relatives carrying H237P: Pt1 in the transmembrane
activator and CAML interactor (TACI) gene (S144X) and Pt2 in the perforin (PRF1) gene (N252S). Both mutations have been
previously associated with immunodeficiencies in homozygosis or compound heterozygosis. Taken together, these data suggest
that caspase-9 mutations may predispose to immunodeficiency by cooperating with other genetic factors, possibly by
downregulating the expression of BAFFR and ICOS.
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INTRODUCTION
Caspases are a family of cysteine-dependent aspartate-directed
proteases present in the cytoplasm as inactive proenzymes; some
are involved in apoptotic induction, whereas others are involved
in cell activation.1–3 In the immune system, apoptosis has a crucial
role in the deletion of autoreactive lymphocytes and in cell-
mediated cytotoxicity. Apoptosis acts via two pathways: the
extrinsic pathway triggered by surface death receptors that belong
to the tumor necrosis factor receptor family, which induce
activation of caspase-8 and -10, and the intrinsic pathway that
proceeds through the mitochondrial release of cytochrome c and
activation of caspase-9.4 Both pathways converge in the activation
of effector caspases (caspase-3, -6 and -7) and are partly
interconnected because caspase-8 cleaves BH3 interacting-
domain death agonist (Bid) and this induces cytochrome c release
from the mitochondria.5–7
Caspases may also exert non-apoptotic functions, such as
influencing cell proliferation, migration and the immune
response.8,9 They are involved in the differentiation of several cell
types, including macrophages, and may have a role in the
secretion of cytokines and growth factors.10–13 Moreover, activa-
tion of caspases in a temporally and spatially restricted manner
may mediate localized cellular remodeling.13
Deleterious caspase-8 gene mutations cause a peculiar immu-
nological phenotype, in which B- and T-cell accumulation in the
lymph nodes and spleen is associated with severe hypogamma-
globulinemia, increased susceptibility to infections and defective
apoptosis and lymphocyte activation in vitro.14 The involvement of
caspase-8 in lymphocyte activation was confirmed by several
reports showing that its inhibitors decrease lymphocyte activation
in vitro and its inactivation causes immunodeficiency in mice.13,15
It has been suggested that this effect may depend on the
inhibition of a caspase-dependent cleavage of proteins involved in
either cell cycle control (such as p27KIP1) or signaling (such as
FADD-like interleukin-1β-converting enzyme-like inhibitory pro-
tein, FLIP). Moreover, caspase-8 is involved in the activation of the
nuclear factor-κ-light-chain-enhancer of activated B cells (NF-κB), a
transcription factor that is crucial for lymphocyte activation.16–18
Caspase-3 has also been suggested to influence the immune
system; its loss in mice results in B- and T-cell accumulation in the
lymph nodes and spleen, ascribed to defective apoptosis for
T cells and to altered regulation of cell cycle for B cells.19
Loss-of-function mutations of the caspase-10 gene (CASP10)
can cause the autoimmune lymphoproliferative syndrome (ALPS;
OMIM no. 601859) due to defective function of the Fas death
receptor.20 In most ALPS patients, the Fas defect is due to
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mutations of the Fas gene, although mutations of the Fas ligand
(FasL) or caspase-10 genes have been occasionaly detected,
whereas the mutated gene is unknown in some patients.20–24
ALPS is characterized by polyclonal accumulation of lymphocytes
in the spleen and lymph nodes, with lymphadenomegaly and/or
splenomegaly and expansion of T-cell receptor αβ+ T cells lacking
CD4 and CD8, namely double-negative T cells. These patients
frequently display autoimmune manifestations during childhood
and may develop lymphomas in adulthood.24 We have also
previously described an incomplete form of ALPS that lacks the
expansion of double-negative T cells, a required criterion for ALPS
diagnosis; this variant form has been named Dianzani auto-
immune lymphoproliferative disease (DALD) by Victor McKusick
(OMIM no. 605233).25,26
Typically, ALPS patients display hypergammaglobulinemia, but
we previously described a subgroup that developed hypogamma-
globulinemia during the course of disease.24,27 This phenotype
resembles that of common variable immunodeficiency (CVID; OMIM
no. 240500), a primary immunodeficiency characterized by defec-
tive antibody production and hypogammaglobulinemia.28,29 CVID
usually manifests during the second and third decade by recurrent
bacterial infections of the upper and lower respiratory tract; up to
20% of CVID patients also display signs of autoimmunity and
lymphoproliferation (splenomegaly). Moreover, both ALPS and CVID
patients may display a skewed distribution of B-cell subsets.30,31
CVID may be caused by variations in several genes involved in
B-cell activation and differentiation, including the CD19/CD21/
CD81, transmembrane activator and calcium modulator and
cyclophilin ligand interactor (TACI or TNFRSF13B), B-cell-activating
factor belonging to the TNF family (BAFF) receptor (BAFFR) and
inducible T-cell costimulator (ICOS) genes.29,32 CD19, CD21 and
CD81 are components of the coreceptor of the B-cell receptor and
are involved in B-cell activation. TACI and BAFFR (or TNFRSF13C)
are expressed by B cells and bind the BAFF cytokine, thereby
having a role in B-cell activation and survival. ICOS is expressed by
activated T cells and has a role in the formation of lymphoid
follicles by binding the ICOS ligand (ICOSL or B7h, or B7H2)
expressed by B cells.32
Other diseases that may display mixed features of lymphopro-
liferation and immunodeficiency are familial hemophagocytic
lymphohistiocytosis (FHL; OMIM no. 603553), due to defective
function of perforin, which leads to ineffective immune
hyperactivation upon viral infection, with tissue damage and a
fatal outcome;33,34 and X-linked lymphoproliferative syndrome
(XLP; OMIM no. 308240), due to the deficiency of either SAP
(SLAM-associated protein) or XIAP (X-linked inhibitor of apoptosis
protein), thereby causing increased susceptibility to Epstein–Barr
virus infection.35 All these cases are intriguing because they show
that autoimmunity/lymphoproliferation and immunodeficiency
overlap in several diseases. The aim of this study was to assess
the involvement of mutations in the caspase-9 gene (CASP9) in the
development of hypogammaglobulinemia and/or lymphoproli-
feration. We began our analysis with patients displaying both
clinical phenotypes and then considered those with either ALPS or
hypogammaglobulinemia. We detected a heterozygous H237P
mutation in two patients who also carried a second heterozygous
mutation: one in the TNFRSF13B gene, which encodes TACI, and
the other in PRF1 gene, which encodes perforin. Analysis of the
patients’ lymphocytes and the transfection experiments of the
mutated CASP9 cDNA in lymphocytes showed that expression of
the mutated caspase-9 protein correlated with the downregula-
tion of BAFFR in B cells and ICOS in T cells, which may be involved
in the patients’ low immunoglobulin (Ig) levels.
RESULTS
Patient analyses
CASP9 variations were searched in the genomic DNA from
seven patients displaying autoimmunity, chronic lymphadeno-
megaly and/or splenomegaly and hypogammaglobulinemia. We
sequenced exons from 2 to 9 and their intron/exon boundaries
but not exon 1, as no amplification was obtained with four
different sets of primers because of its high GC content. We
detected a heterozygous 710A4C nucleotide substitution
(nucleotide position given from the ATG translation initiation site)
in exon 5 in one patient (Pt1) (Figures 1 and 2a, b). This mutation
results in the amino-acid substitution H237P (CASP9H237P) and it
was not detected in any of the 140 healthy donors. This variation
has been described in the dbSNP database as a rare variant with
an allelic frequency o0.01% (rs 146054764).
Pt1 was an 18-year-old male, displaying features of both
ALPS and CVID since the age of 3 years. The signs of ALPS were
chronic thrombocytopenia, lymphadenomegaly, splenomegaly
and expansion of double-negative T cells (8–10%) in the
peripheral blood, whereas those of CVID were severe hypo-
gammaglobulinemia (low IgM, IgG and IgA levels), recurrent
pulmonary infections with bronchiectasia and retarded physical
growth. In his family, the mutation was carried by the father (F1)
and the elder sister (S1a), but not by the mother (M1) or the
younger sister (S1b) (Figure 2b).
Figure 1. CASP9 variation carried by the patients. Graphical representation (not in scale) of caspase-9 gene: (a) boxes represent the exons;
arrows indicate the mutation and protein (b); and numbers indicate the amino-acid positions. CARD, caspase recruitment domain; LD: linker
between the two subunits; LSCD: large subunit catalytic domain; SSCD: small subunit catalytic domain.
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The discovery of a mutation in CASP9 in a subject with signs of
both ALPS and CVID prompted us to extend the analysis to 78
patients with ALPS or DALD, lacking Fas, FasL, caspase-10 and
caspase-8 mutations, and 51 patients with primary hypogamma-
globulinemia, including 45 who fulfilled the diagnostic criteria for
CVID, but displayed no signs of ALPS or DALD. We found the
same mutation (710A4C) in one adult patient (Pt2), who
displayed recurrent otitis media and respiratory infections during
childhood and low serum IgM levels, whereas his IgA and IgG
levels were, respectively, borderline and normal. He never showed
signs of ALPS or DALD and he remained healthy in adulthood until
he developed Burkitt lymphoma at the age of 30. In Pt2’s
family, the mutation was carried by the father (F2) and sister (S2)
but not by the mother (M2) (Figure 2b). Both Pt1 and Pt2 were
Italian but from different geographic origins. No other mutations
in CASP9 were detected in any patient.
Because both Pt1 and Pt2 displayed hypogammaglobulinemia,
we assessed the Ig levels in the available sera of the patients’
healthy family members. The results showed that all the relatives
displayed normal Ig levels, except for individuals S1a and S2, who
carried CASP9H237P and displayed slightly decreased IgA and IgM
levels, respectively (Figure 2c). This analysis was not performed in
individuals F2 and M2 as their sera were not available.
Then, the genetic analysis was extended to the ICOS, TACI and
BAFFR genes, involved in CVID;29,32 FAS, FASL and CASP10 involved
in ALPS;24 PRF1, UNC13D and STX11 (sintaxin 11) involved in
FLH;33,34 and SAP and XIAP involved in XLP.35
Results showed that Pt1 carried two mutations in TACI, a
431C4G and a 577T4C substitution that result in the S144X and
C193R changes, respectively (Figures 2a and b). Homozygosity for
a different base change causing S144X (431C4A) has previously
been associated with CVID and this mutant allele is not
expressed.36 Both mutations were detected in M1 and S1b, but
neither were detected in F1 and S1a, which shows that they were
located at the same allele (Figure 2b). Furthermore, the S144X
mutation was not detected in any of the 100 healthy individuals.
By contrast, Pt2 carried a variation in PRF1, an A4G substitution at
position 755 causing an N252S change (rs150053969) that has
been associated with FLH, ALPS, type 1 diabetes and B-cell
lymphomas.33,37–39 This mutation was detected in M2, but not S2
(Figure 2b). In healthy donors, its allelic frequency was 40.02%
(2/816).
As both patients displayed decreased Ig levels in vivo, we
assessed surface expression of CD19, TACI, BAFFR and ICOS
(involved in CVID) in the patients’ peripheral blood mononuclear
cells (PBMCs) by immunofluorescence and flow cytometry
(Figure 3). In resting PBMCs, we assessed the expression of TACI,
BAFFR and HLA-DR in CD19+ B cells, whereas the expression of
ICOS, HLA-DR and CD25 was assessed in CD3+ T cells from
phytohaemagglutinin (PHA)-activated PBMCs. The results showed
that both patients displayed decreased expression of BAFFR in B
cells and decreased expression of ICOS in activated T cells. By
contrast, expression of TACI was in the normal range in the B cells
of both patients, but it was borderline in Pt1, congruent with his
mutation of the TACI gene. Moreover, B-cell expression of CD19
and HLA-DR, and T-cell expression of CD3, CD8, CD4, HLA-DR and
CD25 were in the normal range in both patients (data not shown).
Lymphocyte activation was assessed in the patients’ PBMCs by
evaluating the response to anti-CD3 monoclonal antibody (mAb)
in terms of proliferation and interleukin (IL)-2 secretion (Figure 4a)
and the response to pokeweed mitogen (PWM) in terms of
proliferation and secretion of IgM and IgG (Figure 4b). The results
showed that all these lymphocyte activation responses were
defective in both patients. Moreover, we evaluated whether the
defective proliferative response to CD3 could be overcome
by CD28 costimulation, or by the addition of exogenous IL-2
Figure 2. Pedigrees of family 1 and family 2. (a) Electropherograms of CASP9, TNFRSF13B (TACI) and PRF1 sequences performed on the genomic
DNA of Pt1 for CASP9 and TNFRSF13B and of Pt2 for PRF1. Black arrows show the heterozygous position. (b) Pedigrees of family 1 and family 2
showing the inheritance of the CASP9H237P mutation; inheritance of the S144X TNFRSF13B and N252S PRF1 mutations are also shown. Circles
represent females; squares males; patients are shown in black. (c) Levels of blood double-negative (DN) T cells and serum Ig in the patients’
families.
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Figure 3. Surface expression of TACI, BAFFR and ICOS in PBMCs from patients and healthy donors. Cytofluorimetric histograms showing the
surface expression of TACI and BAFFR assessed in CD19+ cells and of ICOS in PHA-activated CD3+ T cells by two-color immunofluorescence:
unstained cells (white) and stained cells (black). The graphs on the right show the MFI ratios of the patients and the controls; the gray boxes
indicate the 5th–95th percentile and the dashed lines show the median of 17 controls.
Figure 4. Proliferation and effector properties after stimulation with anti-CD3 mAb or PWM in Pt1 and Pt2. (a) Cell proliferation and IL-2
secretion induced by stimulation of PBMCs with anti-CD3 mAb (1 μgml− 1) and cell proliferation induced by anti-CD3+exogenous IL-2
(10 Uml− 1) and anti-CD3+anti-CD28 (10 μgml− 1) mAb. (b) Cell proliferation and secretion of IgM and IgG induced by stimulation of PBMCs
with PWM (10 μgml− 1). The dotted lines indicate the 5th percentile of the activity displayed by all normal controls (n= 19). Each patient was
analyzed four times using different blood samples and the results are shown as the mean± s.e.
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(10 Uml− 1) because both patients displayed defective IL-2
secretion. The results showed that both exogenous IL-2 and
CD28 costimulation had some effect in both patients and
exogenous IL-2 rescued the defect in Pt2 (Figure 4a).
Functional characterization of CASP9H237P
To assess the function of the mutated protein (CASP9H237P), either
anti-Fas mAb or etoposide was used to activate the extrinsic or the
mitochondrial pathway, respectively, and to trigger apoptosis in
PBMCs from both patients. Then, we analyzed the apoptotic
response in terms of cell loss and activation of caspase-8 (extrinsic
pathway), caspase-9 (mitochondrial pathway) and caspase-3
(effector pathway). Figure 5 shows that both patients displayed
defective activation of caspase-9 and normal activation of
caspase-8 in response to either anti-Fas or etoposide. Moreover,
they displayed defective cell loss and defective activation of
caspase-3 in response to etoposide but not to anti-Fas.
To further assess CASP9H237P function, cDNAs coding for
CASP9H237P or the wild-type protein (caspase-9WT) were cloned
into the pcDNA3.1 vector (MOCK), fused to hemagglutinin (HA)- or
FLAG-tag sequences, respectively (H237PHA and WTFLAG plasmids).
Then, 293T cells, expressing minimal levels of endogenous
caspase-9, were transiently transfected with either MOCK alone
(293TMOCK), WTFLAG plus MOCK (293TWT), H237PHA plus MOCK
(293TH237P) or WTFLAG plus H237PHA (293TWT/H237P). Western blot
analysis showed that spontaneous cleavage of caspase-9, which is
a sign of its autoactivation, was detectable in 293TWT, but not in
293TH237P or 293TWT/H237P expressing cells (Figure 6a). Then, we
assessed cell recovery and activation of caspase-9 in these cells
cultured in the presence and absence of etoposide. Results
showed that cell recovery was significantly lower and caspase-9
activity was higher in 293TWT than in 293TH237P and 293TWT/H237P
either in the presence or in the absence of etoposide
(Figures 6b and c). These data indicate that CASP9H237P is less
active than caspase-9WT and that it exerts a dominant-negative
effect on caspase-9WT. As caspase-9 activity involves caspase-9
interaction with apoptotic protease-activating factor (APAF)-1 to
form the apoptosome, we assessed this interaction by immuno-
precipitating caspase-9 and assessing APAF-1 co-immunoprecipi-
tation by western blot in 293TWT and 293TH237P. Results detected
the co-immunoprecipitation in 293TWT but not in 293TH237P
(Figure 6d), which shows that CASPH237P displays defective
interaction with APAF-1.
To confirm these data, PBMCs from healthy donors were
transfected with a MOCK plasmid carrying green fluorescence
protein (GFP) in the absence (PBMCsGFP) or presence (PBMCsH237P)
of H237PHA and cultured for 5 days in the presence of PWM or
PHA. Then, cell proliferation was assessed by the incorporation of
[3H]thymidine (Tdr). The results showed that cell proliferation was
lower in PBMCsH237P than in PBMCsGFP (Figure 7a). The effect on
the apoptotic response was assessed on PHA-activated PBMCs
(PHA-PBMCs) transfected at day 5 of culture to obtain PBMCsGFP
and PBMCsH237P. Twenty-four hours later, cells were treated with
anti-Fas mAb or etoposide to evaluate cell loss and activation of
caspase-9. Results showed that PHA-PBMCsH237P displayed lower
cell loss and caspase-9 activation than PHA-PBMCsGFP in response
to both treatments (Figures 7b and c). Finally, the effect on
cell cycle was analyzed by assessing the expression of p27KIP1 in
PHA-PBMCs transfected at day 5 to obtain PHA-PBMCsGFP and
PHA-PBMCsH237P, or co-transfected with WTFLAG plus H237PHA
(PHA-PBMCsWT/H237P). Twenty-four hours later, western blot
analysis detected higher levels of p27KIP1 in PHA-PBMCsH237P
and PHA-PBMCsWT/H237P than in PHA-PBMCsGFP (Figure 7d).
To assess whether CASP9H237P influences the expression of
BAFFR, we compared the expression of BAFFR, TACI, HLA-DR and
B7h in CD19+ B cells from resting PBMCsH237P and PBMCsGFP by
Figure 5. Cell loss and caspase-8, -9 and -3 activation induced by anti-Fas mAb or etoposide in Pt1 and Pt2 T cells. PBMCs were activated with
PHA at days 0 (1 μgml− 1) and 8 (0.1 μgml− 1) and cultured in RPMI 1640+10% fetal calf serum (FCS)+exogenous IL-2 (10 Uml− 1). Days after
the second stimulation, cells were treated with either anti-Fas mAb or etoposide. (a) Cell loss was assessed by counting live cells (evaluated by
the trypan blue exclusion test) in each well and (b) caspases activation by fluorimetric assays in cells treated or untreated with etoposide. The
dotted lines indicate the 5th percentile of the activity displayed by normal controls (n= 19). Each patient was analyzed four times using
different blood samples and the results are shown as the mean± s.e.
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two-color immunofluorescence 24 h after the transfection. More-
over, the effect on the expression of ICOS was assessed on PHA-
PBMCs transfected at day 3 of culture to obtain PHA-PBMCsGFP
and PHA-PBMCsH237P. Twenty-four hours later, expression of ICOS,
CD25 and HLA-DR was assessed in CD3+, CD4+ and CD8+ T cells by
two-color immunofluorescence. The results showed that CD19+
PBMCH237P expressed lower levels of BAFFR than CD19+ PBMCsGFP
(Figure 8a), whereas the expression of TACI, HLA-DR, B7h and
CD19 was similar in the two cell preparations (data not shown).
Moreover, CD3+ PHA-PBMCH237P expressed lower levels of ICOS
than CD3+ PHA-PBMCsGFP (Figure 8b), which was detected in both
the CD4+ and CD8+ T-cell subsets (data not shown), whereas
expression of CD3, CD4, CD8, CD25 and HLA-DR was similar in the
two cell preparations (data not shown). To confirm these results,
the transfection experiments were repeated in TonsBCs (B cells
from tonsils) and Raji cells, expressing high levels of BAFFR, and in
PHA-TH (PHA-activated purified CD4+ T helper) cells, expressing
high levels of ICOS. The results demonstrated that the expression
of BAFFR was lower in TonsBCH237P and RajiH237P than in
TonsBCGFP and RajiGFP (Figure 8a) and that the expression of ICOS
was lower in PHA-THH237P than in PHA-THGFP (Figure 8b).
To confirm that defective caspase-9 activity may modulate the
expression of BAFFR and ICOS and cell proliferation, we treated
PHA-activated PBMCs from healthy donors with Z-VAD-FMK
(30 μM), inhibiting caspase-9 and other caspases, at day 3
from activation and assessed BAFFR and ICOS expression, cell
proliferation and the apoptotic response to etoposide at day 5.
Results showed that Z-VAD-FMK significantly decreased BAFFR
and ICOS expression, cell proliferation and cell apoptosis
(Supplementary Figure 1).
DISCUSSION
This work shows that the H237P substitution decreases caspase-9
activity and impairs lymphocyte apoptosis and activation. The
defective enzyme activity caused by this mutation is in line with
the notion that the hymidazolic group of histidine 237 may
coordinate the key cysteine of the catalytic site.40
The defects in caspase-9 activity and apoptotic response were
demonstrated in primary patient lymphocytes, as well as in cell
lines transfected with H237PHA. Transient transfection of 293T cells
showed that CASP9H237P had lower enzymatic and proapoptotic
activity than caspase-9WT and also inhibited the function of
caspase-9WT through a dominant-negative effect. This was
surprising because caspase-9 activation requires aggregation of
the apoptosome, a molecular platform composed of seven
molecules of APAF-1, cytochrome c and ATP. Each APAF-1
molecule binds to one procaspase-9 molecule, which then recruits
another APAF-1 molecule.41 Therefore, recruitment of inactive
forms of caspase-9 or a reduced association with APAF-1 may
affect the overall function of the apoptosome, as has been
previously shown by other authors using deletion mutants of
caspase-9.42 Transient transfection of 293T cells showed that
CASP9H237P, differently from caspase-9WT, is not associated to
APAF-1 at detectable levels.
The defect in lymphocyte activation was shown in the patients’
lymphocytes that displayed defective CD3-induced proliferation
and IL-2 secretion and defective PWM-induced proliferation and Ig
secretion. The effect of defective caspase-9 activity on lymphocyte
activation was confirmed by the decreased proliferative response
displayed by normal PBMCs transfected with CASP9H237P or
treated with the caspase inhibitor Z-VAD-FMK.
Figure 6. CASP9H237P impairs the apoptotic response and caspase-9 activation in 293T-transfected cells. (a) Western blot analysis of cell lysates
obtained from 293T cells transfected with the empty pcDNA3.1 vector or WTFLAG or H237PHA or both are shown. The white arrow shows the
procaspase-9 and the black arrow indicates the cleaved form. (b) Cell recovery and (c) caspase-9 activity evaluated 18 h after transfection, as
indicated in the panel a, and cultured in the presence and absence of etoposide (5 μgml− 1); data are expressed as the mean± s.e. of the
results from six experiments. *Differences vs empty vector; #differences vs WTFLAG (*Po0.05; **Po0.01). (d) Co-immunoprecipitation of
caspase-9 and APAF-1 in cell lysates from 293T cells transfected with WTFLAG or H237PHA. Upper panel shows lysates immunoprecipitated with
anti-caspase-9 and blotted with anti-APAF-1; lower panel is the same blot decorated with an anti-caspase-9 antibody; the black arrows mark
the specific signals and the white arrows mark the heavy and light Ig chains.
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The dual effect of the caspase-9 defect on lymphocyte
apoptosis and activation mimics the defects observed in two
siblings carrying homozygous mutations of the caspase-8 gene.14
They displayed defective lymphocyte apoptosis, as well as
impaired activation of T, B and natural killer cells, defective IL-2
secretion and developed a disease with ALPS, hypogammaglobu-
linemia and increased susceptibility to infections. The hetero-
zygous carriers were healthy.
In Pt1 and Pt2, as in the caspase-8 deficient patients, the
lymphocyte apoptosis and activation defects paralleled a clinical
phenotype with impaired immune function and lymphoprolifera-
tion. The most severe phenotype was displayed by Pt1 with overt
CVID and ALPS. Pt2 displayed milder symptoms displayed by
decreased serum IgM, increased susceptibility to infections during
childhood and development of Burkitt lymphoma in adulthood.
The lymphoma could be a consequence of immunodeficiency, but
might also be favored by an unapparent preneoplastic lympho-
proliferation, which is regarded as a cause of lymphomas.43,44 It is
noteworthy that even the ALPS displayed by Pt1 can be regarded
as a preneoplastic lymphoproliferation because it predisposes
patients to lymphoma development. The involvement of caspase-
9 in lymphoma development is also suggested by the finding that
high expression of Bcl-2 and XIAP, which inhibit caspase-9
activation, and defective apoptotic response to etoposide
correlate with an unfavorable prognostic value in diffuse large
B-cell lymphomas.45
An unexpected effect of the CASP9 mutation was its involve-
ment in decreasing the expression of BAFFR and ICOS. This is
shown by the finding that both patients displayed decreased
expression of these receptors in B cells and activated T cells,
respectively. Moreover, transfection of CASP9H237P or treatment
with Z-VAD-FMK decreased the expression of BAFFR in B cells and
ICOS in activated T cells from normal donors. This effect was
specific because expression of several other cell markers were
unchanged.
The inhibitory effect of CASP9H237P on cell proliferation and
apoptosis was independent of its effect on the expression of
BAFFR and ICOS, as it was also detected in 293T cells, which do not
express those receptors. Moreover, transfection of ICOS in PBMCs
transfected with CASP9H237 rescued the decreased expression of
ICOS but not the decreased proliferative and apoptotic responses
of these cells (data not shown). As suggested for caspase-8, this
effect might be due to inhibition of a caspase-dependent cleavage
of proteins involved in the control of cell cycle, as indicated by the
increased expression of p27KIP1, which is expected to block cell
entry into the S phase, displayed by PBMCs transfected with
CASP9H237P.
BAFFR and ICOS have a role in follicle formation because BAFFR
is expressed by follicular B cells and supports their survival,46
Figure 7. CASP9H237P impairs the proliferative and apoptotic responses and caspase-9 activation in transfected PBMCs. (a) Resting PBMCs from
normal donors were transiently transfected with vectorGFP alone or plus H237PHA (C9). Cell proliferation in response to PWM or PHA was
assessed by incorporation of [3H]thymidine. (b) Cell loss and (c) caspase-9 activity in response to treatment with anti-Fas mAb or etoposide.
Data are expressed as the mean± s.e. (n= 9). (d) Western blot and respective relative expression levels (± s.e.) of p27KIP1 normalized to actin
expression from four independent experiments in transfected PHA-PBMCs. The black arrow indicates the p27KIP1 relative band. Asterisks mark
differences from GFP-transfected cells. The percentage of GFP-positive cells was 52±5% (mean± s.e.) for PBMCsGFP and 54± 4% for
PBMCsH237P.
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whereas ICOS is expressed by T helper follicular cells and interacts
with both cognate and bystander B cells.47 Therefore, the low
expression of BAFFR and ICOS may explain the low Ig levels of our
patients, which seems to be a hallmark of the CASP9 mutation
because it was detected in all of the patients’ family members
carrying the CASP9H237P but not in the others. Unfortunately, we
could not assess BAFFR and ICOS expression in these family
members because their cells were not available.
Penetrance of CASP9H237P seems to be incomplete as the four
carriers in the patients’ families were healthy, although two of
them (S1a and S2) displayed a subclinical defect with a mild
decrease of serum IgM and IgA, respectively. The severity of the
clinical outcome may thus depend on the influence of concurrent
genetic and environmental factors. Congruent with the role of
concurrent genetic factors, Pt1 and Pt2 each carried heterozygous
mutations of a second gene. This was inherited from their
CASP9H237P-free mothers and may have contributed to their
clinical outcome.
Pt1 carried a S144X mutation in TNFRSF13B coding for TACI,
a receptor that binds BAFF and APRIL (a proliferation-
inducing ligand). TACI is expressed on peripheral blood B cells,
particularly on the CD27+ subset. TACI-deficient mice
display humoral immunodeficiency together with autoimmunity
and lymphoproliferation.36,48,49 In humans, several TNFRSF13B
mutations have been associated with both CVID and IgA
deficiency. In particular, Salzer et al.36 detected homozygous
S144X mutations in a patient with hypogammaglobulinemia and
hepatosplenomegaly; his brother, who was healthy, carried the
same mutations and displayed lymphocytosis. The mutation
inserts a stop codon in exon 3 and impairs the expression of
the TACI protein and mRNA.36 In line with this, Pt1 displayed a
borderline expression of TACI in B cells. Pt1 also carried a second
mutation (C193R) in exon 4 of the same allele, but this should be
irrelevant as it is located downstream of the inserted stop codon.
S144X seems non-penetrant in heterozygosity as shown both by
Salzer et al.36 and by our analysis of heterozygous patients M1 and
S1b. Therefore, the finding that Pt1 is the only member of the
family with both S144X and CASP9H237P suggests that the two
mutations may have cooperated in the disease development of
Pt1, possibly through the borderline expression of TACI and the
decreased expression of BAFFR and ICOS, which are all involved in
B-cell function.
Pt2 carried a heterozygous mutation of PRF1 coding for perforin,
which is stored in the lytic granules of cytotoxic cells and involved
in cell-mediated cytotoxicity.33,34 Biallelic PRF1 mutations cause
FHL, an immunodeficiency characterized by hemophagocytosis,
fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia,
hypofibrinogenemia, frequent nervous system involvement and
Figure 8. Surface expression of BAFFR and ICOS in lymphocytes of healthy donors after transient transfection of CASP9H237. (a) Expression of
BAFFR in CD19+ PBMCs, Raji cells and total TonsBCs transiently transfected with vectorGFP alone or plus H237PHA (C9). (b) Expression of ICOS in
CD3+ PBMCs (PHA-PBMCs) or purified CD4+ T cells (PHA-TH) transiently transfected with vectorGFP alone or with H237PHA (C9). Upper panels
show representative cytofluorimetrc histograms of the unstained cells (black) and the stained cells (white); numbers indicate the mean
fluorescence intensity ratio (MFI-R). Lower panels show the mean± s.e. of MFI-R of BAFFR or ICOS expression from nine experiments; results
are relative to the BAFFR or ICOS expression displayed by GFP-transfected set at 100% (dotted line) in each experiment. Asterisks mark
differences from GFP-transfected cells. The 100% value corresponded to MFI ratio= 65± 8 for BAFFR and 11± 2 for ICOS.
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increased frequency of lymphomas.33 The disease is ascribed to
the decreased capacity of cytotoxic cells to clear viral infections,
whose persistence may support the lymphoproliferative picture.
FHL is a recessive disease and subjects carrying heterozygous PRF1
mutations are generally healthy; however, inherited PRF1 muta-
tions have also been associated with the development of
lymphomas and ALPS.37 In lymphomas, they can be either
heterozygous or homozygous, whereas they are heterozygous in
ALPS but are associated with inherited defects that affect Fas
function. A similar role as a risk factor for ALPS has also been
described for the UNC13D gene encoding for MUNC13-4, which is
involved in perforin secretion and the development of a genetic
variant of FHL.50,51 The N252S mutation has been detected in FHL,
ALPS and lymphomas.33,37–39 It occurs within the membrane
attack complex, a region critically involved in the pore-forming
activity of perforin, but its functional significance has been
debated because it has been associated with normal natural killer
activity.52 In Pt2, a double caspase-9 and perforin defect may be
involved in the development of his Burkitt lymphoma as both
mutations may impair the immune response and favor
lymphoproliferation.
The clinical phenotype of our heterozygous patients is very
different from the high perinatal lethality, severe alteration of
central nervous tissue development, and minor alterations of the
immune system impairment displayed by the caspase-9− /−
mice. These differences, however, may reflect the residual
caspase-9 activity displayed by our heterozygous patients and
the cooperation of their second mutations.53
In conclusion, our data show that caspase-9 is involved in both
lymphocyte apoptosis and activation and that its defective activity
can induce a clinical pattern of immunodeficiency and lympho-
proliferation qualitatively similar to that induced by defective
caspase-8 activity.
MATERIALS AND METHODS
Patients
We analyzed 136 unrelated Italian patients: 7 with autoimmunity, chronic
lymphadenomegaly and/or splenomegaly and hypogammaglobulinemia,
78 with ALPS or DALD, lacking Fas, FasL, caspase-10 and caspase-8
mutations and 51 with primary hypogammaglobulinemia. ALPS/DALD
patients were diagnosed using the criteria established at the 2009 ALPS
NIH International Workshop.24 A total of 140 healthy individuals were used
as controls.
The study was planned according to the guidelines of the local ethical
committee, Azienda Ospedaliera della Carità, of Novara that approved the
study (Protocol 106/CE). Written, informed consent was signed by the
patients or by their parents if they were minors.
Sequence analyses
Specific primers were used to amplify the exons and intron boundaries of
CASP9 (gene ID: 842), FAS (ID: 355), FASL (ID: 356), CASP10 (ID: 843),
TNFRS13B (TACI) (ID: 23495), TNFRSF13C (BAFFR) (ID: 115650), ICOS (ID:
29851), PRF1 (ID: 5551), UNC13D (ID: 201294), STX11 (ID: 8676), SH2D1A
(SAP) (ID: 4068) and XIAP (ID: 331) genes. The PCR products were
sequenced with the ABI PRISMR BigDyeTM Terminator Kit (Applied
Biosystems, Foster City, CA, USA) on an automatic sequencer, Applied
Biosystems 3100 Genetic Analyzer (Applied Biosystems), using the same
primers, except for exon 3 of PRF1 for which we used also an internal
primer.
Cells
PBMCs were obtained by density gradient centrifugation from patients’
blood and buffy coats, provided by the local Blood Transfusion Service
(Novara, Italy). Total CD4+ T cells from healthy controls were purified using
the CD4+ T Cell Isolation Kit II (Miltenyi Biotec, Teterow, Germany). This
approach provided 497% cells displaying the CD3+CD4+CD45RA+
CD45RO+CD14−CD16− phenotype, as assessed by direct immunofluores-
cence and flow cytometry. B cells were purified, after homogenization, by
density gradient centrifugation from the tonsils of patients undergoing
tonsillectomy in the Otolaryngology Clinic of Azienda Ospedaliera della
Carità, Novara, Italy. Cell surface markers were assessed by immunofluor-
escence and flow cytometry using the appropriate mAb to BAFFR
(BioLegend, San Diego, CA, USA), ICOS (eBioscience, San Diego, CA, USA),
B7h (R&D Systems, Minneapolis, MN, USA), TACI (BioLegend), CD19
(ImmunoTools, Friesoythe, Germany), CD3 (Becton Dickinson, Franklin
Lakes, NJ, USA), CD4 (Sigma, St Louis, MO, Canada), CD8 (Invitrogen,
Burlington, ON, Canada), CD25 (BioLegend) and HLA-DR (Becton
Dickinson). In some experiments, cells were treated with Z-VAD-FMK
(30 μm) (Enzo Life Sciences, Florence, Italy).
Antigenic density was expressed as the mean fluorescence intensity
ratio, using the following formula: mean fluorescence intensity of
sample histogram (arbitrary units)/mean fluorescence intensity of control
histogram (arbitrary units).
Cell death assays
PBMCs (1 × 105) were incubated in flat-bottom 96-well plates with control
medium (200 μl) with or without anti-Fas mAb (0.5 μgml− 1) (CH11;
UPSTATE Waltham, MA, USA) or with etoposide (5 μgml− 1) (Sigma) in the
presence of exogenous IL-2 (1 Uml− 1) to minimize spontaneous cell death.
Eighteen hours later, the live cells were counted by the trypan blue
exclusion test and live cells were detected using flow cytometry by
excluding those cells that were propidium iodide (Becton Dickinson) and
annexin V-FITC positive (Becton Dickinson); the two methods gave
overlapping results. These assays were performed in duplicate. In some
experiments, PBMCs were treated with Z-VAD-FMK (30 μM) (Enzo Life
Sciences). In transfected human embryonic kidney 293T cells (ATCC; no.
CRL-11268, Manassas, VA, USA), cell death assay was assessed 48 h after
transfection, and in the last 18 h, etoposide (5 μgml− 1) or no stimulus was
added to the media of culture.
The specific cell loss % was calculated as follows: 100− (total live cell
count in the assay well/total live cell count in the control well) × 100.
Caspase-9, -3 and -8 activity was assessed in cell lysates using a
fluorimetric assay (MBL, Watertown, MA, USA). At least three control
samples, using PBMCs from different healthy donors, were run in parallel.
In transfected human embryonic kidney 293T cells, caspase-9 activity was
assessed 24 or 48 h after transfection to evaluate activation after treatment
with etoposide (5 μgml− 1) or spontaneous autoactivation, respectively.
PBMCs activation assays
PBMCs (1×105 per well) were cultured in flat-bottom 96-well microplates
with RPMI 1640+10% fetal calf serum in the presence or absence of the
appropriate stimulus. The anti-CD3 mAb (OKT3 1 μgml− 1 in phosphate-
buffered saline) (ATCC; no. CRL-8001) was precoated into the plates by
overnight incubation at 4 °C. PHA and PWM (Sigma) were used at 1 and
10 μgml− 1, respectively. PBMC proliferation was assessed in triplicate by
evaluating the uptake of [3H]TdR (1 μCi per well) (Perkin-Elmer, Waltham,
MA, USA) in the last 6 h of culture on days 3 and 5 for OKT3- or PHA- and
PWM-treated cells, respectively; the cells were harvested and radioactivity
was detected with a β-counter (Perkin-Elmer). IL-2 secretion was evaluated
by performing an enzyme-linked immunosorbent assay on the day 3 culture
supernatants (Beckton Dickinson). In PWM- treated cells, IgG, IgM and IgA
secretion was evaluated by enzyme-linked immunosorbent assay of the day
5 supernatants (Rockland, Gilbertsville, PA, USA). In some experiments, cells
were treated with Z-VAD-FMK (30 μM) (Enzo Life Sciences).
Caspase-9 cloning and transfection
Total RNA was extracted from Pt1 PBMCs using the NucleoSpin RNA II Kit
(Macherey-Nagel, Düren, Germany) and reverse transcribed with the
ThermoScript RT-PCR System (Invitrogen, Milan, Italy). CASP9 was amplified
with the same reverse primer and with two alternative forward primers,
one adding the HA-tag and the other the FLAG-tag. Because Pt1 was
heterozygous for CASP9H237P, both the wild-type (FLAG-tagged) and the
mutated (HA-tagged) amplimers were obtained. These cDNAs were cloned
into the pcDNA3.1 vector (Invitrogen) and sequenced.
The 293T cells were cultured in Dulbecco’s modified essential medium
(Invitrogen) supplemented with 10% fetal calf serum at 37 °C. A total of
3 × 106 cells were plated in 90mm dishes and transfected with 15 μg of the
empty vector, the WTFLAG vector, the H237PHA vector or a combination of
them using the Lipofectamine 2000 Kit (Invitrogen).
PBMCs, CD4+ T cells, TonsBCs and Raji cells (ATCC; no. CCL-86) were
cultured in RPMI 1640 medium+10% fetal calf serum and transfected using
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the Amaxa Cell Line Nucleofactor Kit V (Lonza, Basel, Switzerland),
according to the manufacturer’s instructions. Briefly, 4 μg of each
construct were co-transfected with 1 μg of the pEGFP vector (Invitrogen).
Transfection efficiency was analyzed by cytofluorimetric evaluation of the
proportion of GFP-expressing cells.
After 30 h, adherent and floating cells were harvested into ice-cold AKT
buffer (20 mM Tris, pH 7.5, 5 mM ethylenediaminetetraacetic acid, 150mM
NaCl, 1% Triton X-100, 10% glycerol, 0.5 mM dithiothreitol, 1 mM
phenylmethanesulfonyl fluoride), 1 μgml− 1 leupeptin, 1 μgml− 1 aprotinin,
1 μgml− 1 pepstatin) for 20min and sonicated three times. Cell debris was
removed by centrifugation and equal amounts of the cleared lysates were
heated for 5 min at 95 °C.
Western blotting and immunoprecipitation
Protein extracts from 293T cells and PBMCs were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to Hybond-
C extra membranes (Amersham Pharmacia Biotech, Piscataway, NJ, USA),
blotted with anti-caspase-9 (1 μgml− 1) (Sigma), anti-HA (0.5 μgml− 1)
(Millipore, Billerica, MA, USA), anti-FLAG (1 μgml− 1) (Sigma), anti-APAF-1
(1 μgml− 1) (Sigma), anti-p27KIP1(1 μgml− 1) (Sigma) or anti-actin
(0.5 μgml− 1) (Sigma). A peroxidase-conjugated anti-mouse or anti-rabbit
(GE Healthcare, Piscataway, NJ, USA) were used as a secondary antibody
(GE Healthcare) and revealed by chemiluminescence.
In the immunoprecipitation experiments, transfected 293T cells were
lysed in IPB buffer (10mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40, 0.5%
sodium deoxycholate, 1 mM phenylmethanesulfonyl fluoride, 1 μgml− 1
leupeptin, 1 μgml− 1 aprotinin, 1 μgml− 1 pepstatin). Five micrograms of
lysate was precleared with Sepharose-ProtG beads (GE Healthcare) and
then incubated with 2 μg anti-caspase-9 mAb (Sigma), anti-HA mAb
(Sigma) or the polyclonal anti-FLAG (Sigma) for 1 h at 4 °C and with 20 μl of
protein G beads (GE Healthcare) for a further hour at 4 °C. Beads were
washed three times, boiled in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis sample buffer, separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and blotted with anti-APAF-1 (Sigma)
and anti-caspase-9 (Sigma) antibodies.
Statistical analysis
Statistical analysis was performed using the analysis of variance followed
by Dunnett’s multiple comparison test, and paired t-test for analysis of
transfected lymphocytes. The results are shown as the mean± s.e.
Genotype distributions were analyzed using the Fisher’s exact test. All
P-values are two-tailed, and the significance cutoff was *Po0.05 and
**Po0.01. Statistical analysis was performed with GraphPad Instat
(GraphPad Software, San Diego, CA, USA) software.
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